CVE-2025-9735A weakness has been identified in O2OA up to 10.0-410.
Updated under an hour ago ()
This data is behind schedule: last updated 2026-10-22 20:23 UTC. We are working on it.Behind: National Vulnerability Database (CVE API 2.0, CPE API 2.0).
Does this affect you?
It affects zoneland o2oa. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Free account, 1 product
A weakness has been identified in O2OA up to 10.0-410. This affects an unknown function of the file /x_query_assemble_designer/jaxrs/table of the component Personal Profile Page. This manipulation of the argument description/applicationName/queryName causes cross site scripting. The attack may be initiated remotely. The exploit has been made available to the public and could be exploited. The vendor replied in the GitHub issue (translated from simplified Chinese): "This issue will be fixed in the new version."
- CVSS
- 5.4 MEDIUM (v3.1, NVD)CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N
- Weakness (CWE)
- CWE-79, CWE-94
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- Not given
- NVD analysis
- Analyzed
- Record last updated
- Oct 19, 2026
- First seen by InfoSec Signals
- Oct 19, 2026
Affected products
zoneland o2oa zoneland:o2oa | through 10.0-410 | NVD |
References
- https://github.com/o2oa/o2oa/issues/187exploit, issue-tracking, third-party-advisory
- https://github.com/o2oa/o2oa/issues/187#issue-3332984961exploit, issue-tracking, third-party-advisory
- https://vuldb.com/?ctiid.322034permissions-required, vdb-entry
- https://vuldb.com/?id.322034third-party-advisory, vdb-entry
- https://vuldb.com/?submit.637249third-party-advisory, vdb-entry
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.